Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled study of SCO-267 in healthy adults and subjects with impaired glucose tolerance
jRCT2080224969Phase 1Completed
- Sponsor
- SCOHIA PHARMA, Inc.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCO-267 in prediabetes (4 arms), sponsored by SCOHIA PHARMA, Inc. Primary endpoints: Safety and tolerability of SCO-267 and Pharmacokinetics of SCO-267. Started Nov 2019; status: completed.
02
Drugs
SCO-267
03
Conditions
prediabetes
Beyond the preview
Go deeper on jRCT2080224969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224969.